TrialInternational journal of clinical oncology2016

Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.

Naoya Yamazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.